| Quinoline antimalarials increase the antibacterial activity of ampicillin OA Olateju, CP Babalola, OO Olubiyi, OA Kotila, DA Kwasi, AO Oaikhena, ... Frontiers in Microbiology 12, 556550, 2021 | 23 | 2021 |
| Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study OA Olateju, Z Zeng, OO Adenaiye, TJ Varisco, M Zakeri, SS Sujit Frontiers in Oncology 12, 1092355, 2023 | 4 | 2023 |
| Racial and ethnic differences in colon cancer surgery type performed and delayed treatment among people 45 years old and older in the USA between 2007 and 2017: Mediating … P Fwelo, O Afolayan, KOS Nwosu, AA Ojaruega, O Ahaiwe, OA Olateju, ... Surgical Oncology 50, 101983, 2023 | 3 | 2023 |
| Population-based assessment of the burden of COVID-19 infection in African countries: a first-year report card and public health implications O Mgbere, OC Nwabuko, OA Olateju, OE Adepoju, W Liaw, C Darkoh, ... Therapeutic Advances in Infectious Disease 10, 20499361231202116, 2023 | 2 | 2023 |
| Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors OA Olateju, Z Zeng, JD Thornton, O Mgbere, EJ Essien BMC cancer 23 (1), 655, 2023 | 1 | 2023 |
| EPH189 Assessment of Burden of COVID-19 Infection and the Dynamics in African Union Member States O Mgbere, OC Nwabuko, O Olateju, O Adepoju, W Liaw, C Darkoh, ... Value in Health 26 (6), S198, 2023 | 1 | 2023 |
| Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors OA Olateju, O Mgbere, JD Thornton, Z Zeng, EJ Essien American Journal of Clinical Oncology 47 (11), 517-525, 2024 | | 2024 |
| Pharmacist intervention to improve controlled substance dispensing and use practices in Texas: A pilot study JD Thornton, NZY Smith, OA Olateju, MA Wanat, AM Altaie, TJ Varisco JAPhA Practice Innovations 1 (4), 100019, 2024 | | 2024 |
| Risk Factors Associated with Incident Prescription Opioid Use Among Patients Receiving Prescription Drugs for Attention-Deficit/Hyperactivity Disorder (ADHD) M Shrestha, C Shen, D Kang, D Leslie, T Varisco, O Olateju, M Wanat, ... 2024 Annual Research Meeting, 2024 | | 2024 |
| Impact of Mandatory Review of Prescription Drug Monitoring Program on Controlled Substances-Related Queries in Texas O Olateju, M Shrestha, A Altaie, T Varisco, D Thornton 2024 Annual Research Meeting, 2024 | | 2024 |
| Trajectories of Buprenorphine Adherence, Persistence, and Associated Health Outcomes Among Medicaid Populations O Olateju, D Thornton 2024 Annual Research Meeting, 2024 | | 2024 |
| PCR149 Buprenorphine Adherence Trajectories, Persistence, and Healthcare Expenditures Among Commercially Insured Patients With Opioid Use Disorder O Olateju, JD Thornton Value in Health 27 (6), S323-S324, 2024 | | 2024 |
| EPH37 Determinants of COVID-19 Vaccine Acceptance Among Nigerian Adults OK Afolayan, OA Olateju, YA Adekunle Value in Health 27 (6), S159-S160, 2024 | | 2024 |
| HPR123 Impact of Mandated Use of the Texas Prescription Monitorsing Program on Carisoprodol Dispensing in Texas Z Zeng, T Temedie-Asogwa, O Olateju, T Varisco, JD Thornton Value in Health 27 (6), S215, 2024 | | 2024 |
| The Affordable Care Act and income-based disparities in health care coverage and spending among nonelderly adults with cancer OA Olateju, C Shen, JD Thornton Health Affairs Scholar 2 (5), qxae050, 2024 | | 2024 |
| Understanding the financial barriers to treatment among individuals with opioid use disorder: A focus group study P Anyanwu, V Tata, O Olateju, T Varisco, LR Gilbert, ME Ogunsanya, ... | | 2024 |
| First-line Treatment Patterns and Associated Survival Among Older Patients with Advanced Cancer OA Olateju, OO Mgbere, JD Thornton, EJ Essien Research in Social and Administrative Pharmacy 20 (4), e101, 2024 | | 2024 |
| Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre-and post-regulatory approval OA Olateju, Z Zeng, M Zakeri, SS Sansgiry Clinical and Translational Oncology, 1-13, 2024 | | 2024 |
| Productivity Losses Associated with Prescription Controlled Substance Use: A Nationally Representative Cost Analysis Using MEPS 2010-2019 M Shrestha, T Varisco, O Olateju, P Bhatt, C Shen, D Thornton 2023 Annual Research Meeting, 2023 | | 2023 |
| EE382 Healthcare Expenditure Burden of Melanoma in the Era of Immune Checkpoint Inhibitors O Olateju, J Li, JD Thornton, RR Aparasu Value in Health 26 (6), S129, 2023 | | 2023 |
J. Douglas ThorntonUniversity of Houston College of Pharmacy在 central.uh.edu 的电子邮件经过验证
